Relmada Therapeutics CMO – Urology Raj Pruthi departs effective Sept 3, 2026

RELMADA THERAPEUTICS, INC.

Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026.
No replacement or successor for the CMO – Urology role was named in the filing.
Departure was reported under Item 8.01; no reason or transition details provided.

item 8.01

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-097851

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.